Physician
Oncology
Dr. Kert D. Sabbath, MD
|
|
Give Review
Kert Sabbath practices Oncology. He went to Boston University School of Medicine. Boston University School of Medicine is ranked 30/52 in Research/PrimaryCare. He received 4 awards: "Top Doctors: New York Metro Area", "CMS Meaningful Use Stage 1 Certification", "Top MD" and "Most Compassionate Doctor". Kert D. Sabbath is a published physician as well. He has 17 publications published. The latest was: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Dr. Kert D. Sabbath accepts all Medicare patients.
Publications
- Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal Cancer.
- Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal Cancer.
- A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung Cancer following treatment with platinum-based chemotherapy.
- Prognostic significance of circulating tumor cells in patients with metastatic colorectal Cancer.
- Differential expression of HLA-DR antigens in subsets of human CFU-GM.
- Clonogenic cells in Acute myeloblastic leukaemia.
- Identification and purification of human erythroid progenitor Cells by monoclonal antibody to the transferrin receptor (TU 67).
- Heterogeneity of clonogenic cells in Acute myeloblastic leukemia.
- Effects of recombinant human GM-CSF on proliferation of clonogenic cells in Acute myeloblastic leukemia.
- Potentially curable neoplasms.
- Continuous-infusion cisplatin and bolus 5-fluorouracil in coloRectal carcinoma.
- Cytotoxic murine monoclonal antibody LAM8 with specificity for human small Cell carcinoma of the lung.
- Selective cytotoxicity of murine monoclonal antibody LAM2 against human small-Cell carcinoma in the presence of human complement: possible use for in vitro elimination...
- Combined modality preoperative therapy for unresectable rectal Cancer.
- A monoclonal antibody reactive with normal and leukemic human myeloid progenitor Cells.
- Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroLeukemia cells.
Schools
Boston University School Of Medicine
Boston City Hospital
Massachusetts General Hospital
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors: New York Metro Area
- CMS Meaningful Use Stage 1 Certification
- Top MD
- Most Compassionate Doctor
Education
-
Massachusetts General Hospital -
Boston University Medical Center -
Boston University School of Medicine
Hospital
-
Yale-New Haven Hospital
Drug Facts
| NPI NUMBER | 1831121052 | |
| NPPES Provider LastName | SABBATH | |
| NPPES Provider FirstName | KERT | |
| NPPES Provider ZIPCode | 067082948 | |
| NPPES Provider State | CT | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1575.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 98.0 | |
| Percent Opioid Claims | 6.22 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1831121052 |
| Last Name Of The Provider | SABBATH |
| First Name Of The Provider | KERT |
| View All |
Similar Doctors
|
|
Dr. Anamika Katoch, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph J. Bowen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sylvester J. Ryan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Frank Alfano |